Literature DB >> 17299377

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.

Q Ma1, D F Wyszynski, J J Farrell, A Kutlar, L A Farrer, C T Baldwin, M H Steinberg.   

Abstract

The increase in fetal hemoglobin (HbF) in response to hydroxyurea (HU) varies among patients with sickle cell anemia. Twenty-nine candidate genes within loci previously reported to be linked to HbF level (6q22.3-q23.2, 8q11-q12 and Xp22.2-p22.3), involved in metabolism of HU and related to erythroid progenitor proliferation were studied in 137 sickle cell anemia patients treated with HU. Three-hundred and twenty tagging single nucleotide polymorphisms (SNPs) for genotyping were selected based on HapMap data. Multiple linear regression and the nonlinear regression Random Forest method were used to investigate the association between SNPs and the change in HbF level after 2 years of treatment with HU. Both methods revealed that SNPs in genes within the 6q22.3-23.2 and 8q11-q12 linkage peaks, and also the ARG2, FLT1, HAO2 and NOS1 genes were associated with the HbF response to HU. Polymorphisms in genes regulating HbF expression, HU metabolism and erythroid progenitor proliferation might modulate the patient response to HU.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17299377     DOI: 10.1038/sj.tpj.6500433

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  40 in total

1.  Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.

Authors:  Katherine L Ender; Margaret T Lee; Sujit Sheth; Maureen Licursi; Jennifer Crotty; Sandra Barral; Nancy S Green
Journal:  J Pediatr Hematol Oncol       Date:  2011-10       Impact factor: 1.289

2.  The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.

Authors:  Tohru Ikuta; Adekunle D Adekile; Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Betsy Clair; Abdullah Kutlar; Nadine Odo; C Alvin Head
Journal:  Blood Cells Mol Dis       Date:  2011-09-25       Impact factor: 3.039

Review 3.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

4.  Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach.

Authors:  Belinda Giardine; Joseph Borg; Douglas R Higgs; Kenneth R Peterson; Sjaak Philipsen; Donna Maglott; Belinda K Singleton; David J Anstee; A Nazli Basak; Barnaby Clark; Flavia C Costa; Paula Faustino; Halyna Fedosyuk; Alex E Felice; Alain Francina; Renzo Galanello; Monica V E Gallivan; Marianthi Georgitsi; Richard J Gibbons; Piero C Giordano; Cornelis L Harteveld; James D Hoyer; Martin Jarvis; Philippe Joly; Emmanuel Kanavakis; Panagoula Kollia; Stephan Menzel; Webb Miller; Kamran Moradkhani; John Old; Adamantia Papachatzopoulou; Manoussos N Papadakis; Petros Papadopoulos; Sonja Pavlovic; Lucia Perseu; Milena Radmilovic; Cathy Riemer; Stefania Satta; Iris Schrijver; Maja Stojiljkovic; Swee Lay Thein; Jan Traeger-Synodinos; Ray Tully; Takahito Wada; John S Waye; Claudia Wiemann; Branka Zukic; David H K Chui; Henri Wajcman; Ross C Hardison; George P Patrinos
Journal:  Nat Genet       Date:  2011-03-20       Impact factor: 38.330

Review 5.  Fetal hemoglobin in sickle cell anemia.

Authors:  Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

6.  Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster.

Authors:  Nadia Solovieff; Jacqueline N Milton; Stephen W Hartley; Richard Sherva; Paola Sebastiani; Daniel A Dworkis; Elizabeth S Klings; Lindsay A Farrer; Melanie E Garrett; Allison Ashley-Koch; Marilyn J Telen; Supan Fucharoen; Shau Yin Ha; Chi-Kong Li; David H K Chui; Clinton T Baldwin; Martin H Steinberg
Journal:  Blood       Date:  2009-12-16       Impact factor: 22.113

7.  Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience.

Authors:  E Papadopoulou; A Teli; S Theodoridou; N Gompakis; M Economou
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

8.  High-density SNP genotyping to define beta-globin locus haplotypes.

Authors:  Li Liu; Shalini Muralidhar; Manisha Singh; Caprice Sylvan; Inderdeep S Kalra; Charles T Quinn; Onyinye C Onyekwere; Betty S Pace
Journal:  Blood Cells Mol Dis       Date:  2008-10-01       Impact factor: 3.039

9.  Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Authors:  Jane A Little; Kristine Partovi Hauser; Sabrina E Martyr; Amy Harris; Irina Maric; Claudia R Morris; Jung H Suh; James Taylor; Oswaldo Castro; Roberto Machado; Gregory Kato; Mark T Gladwin
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

10.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.